Condition
Camurati-Engelmann Syndrome
Orthopaedics
Overview
An autosomal dominant form of dysplasia that is characterized by progressive thickening of diaphyseal cortex of long bones. Mutations in the gene that encodes TRANSFORMING GROWTH FACTOR BETA1 are one cause of this disorder.
This information is general and should not be treated as medical advice. Always speak directly with a qualified healthcare professional before making decisions about treatment, diagnosis, procedures, medicines or care.
Quick facts about Camurati-Engelmann Syndrome
- Topic type
- Condition
- Category
- Orthopaedics
- MeSH classification
- C05.116.099.708.180|C16.320.144
Preparing for an appointment about Camurati-Engelmann Syndrome
If you are speaking with a healthcare professional about Camurati-Engelmann Syndrome, it can help to prepare a few details in advance.
- Write down your symptoms and when they started.
- Bring details of any medicines, supplements or previous treatments.
- Ask what tests or assessments may be needed.
- Ask what treatment or management options may be suitable.
- Ask when you should seek urgent medical help or follow-up care.
Finding care related to Camurati-Engelmann Syndrome
EuroCareFinder helps patients explore clinics and healthcare providers across Europe. Some topics link directly to services offered by clinics, while others may be connected through related specialties, treatments or procedures.
Explore clinics across Europe
Browse the wider EuroCareFinder healthcare network using the interactive map.
Clinics related to Camurati-Engelmann Syndrome
No clinics are currently linked directly to Camurati-Engelmann Syndrome on EuroCareFinder.
As more clinics add detailed services, related providers may appear here.
Related topics
Explore healthcare providers
Use EuroCareFinder to browse clinics by country, specialty and available services.
Source: Medical Subject Headings (MeSH), produced by the U.S. National Library of Medicine. EuroCareFinder is not endorsed by the National Library of Medicine. MeSH version: 2026.